NCT06698575 - A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes | Biotech Hunter

Enrollment

146

Participants

Timeline

Start Date

December 8, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Recurrent Genital Herpes Simplex Type 2

Interventions

DRUG

ABI-1179

Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

DRUG

ABI-1179 Placebo

Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Trial Locations (18)

1010

RECRUITING

New Zealand Clinical Research, Auckland

2010

RECRUITING

East Sydney Doctors, Darlinghurst

RECRUITING

Taylor Square Private Clinic, Surry Hills

RECRUITING

Momentum Clinical Research, Sydney

2500

RECRUITING

Canopy Clinical Wollongong, Wollongong

3010

RECRUITING

Pacific Clinical Research Network, Rotorua

3021

RECRUITING

Momentum Sunshine, Melbourne

3050

RECRUITING

Royal Melbourne Hospital, Parkville

3200

RECRUITING

Pacific Clinical Research Network, Hamilton

4414

RECRUITING

Momentum Palmerston North, Palmerston North

5018

RECRUITING

Pacific Clinical Research Network, Upper Hutt

5036

RECRUITING

Momentum Kapiti, Waikanae

7011

RECRUITING

Pacific Clinical Research Network, Nelson

8011

RECRUITING

New Zealand Clinical Research, Christchurch

14609

RECRUITING

Rochester Clinical Research, Rochester

64114

RECRUITING

Alliance for Multispecialty Research, Kansas City

98104

RECRUITING

Seattle Clinical Research Center, Seattle

RECRUITING

University of Washington Virology Research Clinic, Seattle